Postoperative Treatment of Thyroid Cancer

Risk-Stratified Approach to Differentiated Thyroid Cancer (DTC)

The American Thyroid Association recommends postoperative treatment of differentiated thyroid cancer based on risk stratification, including radioactive iodine (RAI) ablation, TSH suppression therapy, and structured surveillance with thyroglobulin monitoring and neck ultrasound 1, 2
High-risk patients with T3-T4 tumors, extrathyroidal extension, lymph node metastases, incomplete resection, or distant metastases should receive RAI ablation at doses of 100-200 mCi (3.7-7.4 GBq) 1, 3
Intermediate-risk patients with T1 >1 cm or T2 tumors, aggressive histology, or multifocal disease require individualized decisions, though RAI is generally recommended 1, 2
Very low-risk patients with unifocal T1 ≤1 cm, intrathyroidal, favorable histology, and no metastases should not receive RAI ablation 2, 4, 5

Preparation for RAI can be accomplished with recombinant human TSH (rhTSH) while continuing levothyroxine, which is equally effective as thyroid hormone withdrawal and avoids hypothyroid symptoms 4, 5
Lower doses of 50 mCi may be equally effective as 100 mCi when using rhTSH preparation, even with lymph node metastases 4, 5

The American Thyroid Association recommends TSH suppression therapy with levothyroxine, with the degree of suppression depending on the risk of recurrence 3, 2, 6
High-risk patients with persistent structural disease should have TSH <0.1 mIU/L 3, 2, 6
Intermediate-risk patients with biochemical incomplete or indeterminate response should have TSH 0.1-0.5 mIU/L 3, 6
Low-risk patients with excellent response to therapy should have TSH 0.5-2.0 mIU/L (normal range) 3, 6

The American Thyroid Association recommends surveillance with thyroid function tests (FT3, FT4, TSH) at 2-3 months post-treatment, and comprehensive evaluation including physical examination, neck ultrasound, and basal and rhTSH-stimulated serum thyroglobulin (Tg) measurement at 6-12 months 1, 2, 7
High-sensitivity Tg assays (<0.2 ng/mL) can replace TSH-stimulated testing to verify absence of disease 3

The American Thyroid Association recommends levothyroxine to maintain TSH in the normal range (0.5-2.0 mIU/L) for medullary thyroid cancer, as C cells lack TSH receptors 7, 2, 6
Postoperative surveillance relies on calcitonin (CT) and CEA monitoring, with CT <150 pg/mL indicating limited evaluation to careful neck ultrasound, and CT >150 pg/mL indicating screening for distant metastases with cross-sectional imaging 7, 2

The American Thyroid Association recommends aggressive postoperative management for poorly differentiated thyroid cancer, including TSH suppressive therapy with levothyroxine, consideration of external beam radiotherapy (EBRT) for unresectable or persistent locoregional disease, and enrollment in clinical trials of novel therapies 1, 7

The American Thyroid Association recommends high-dose EBRT with or without concurrent chemotherapy for anaplastic thyroid cancer, delivered as soon as possible after surgery, with intensity-modulated radiation therapy (IMRT) as the recommended approach 3

The American Thyroid Association recommends lenvatinib and sorafenib as standard first-line systemic therapies for RAI-refractory DTC with progressive disease, with criteria for RAI-refractory disease including non-RAI-avid lesions, loss of ability to concentrate RAI, and progression despite RAI avidity 3
The American Thyroid Association recommends surgery combined with RAI therapy as the primary treatment for recurrent locoregional disease, with supplement of EBRT if surgery is incomplete or RAI uptake is absent 1, 2
The American Thyroid Association recommends consideration of locoregional therapies (surgery, EBRT, radiofrequency ablation) for oligometastatic disease or symptomatic lesions, and bone metastases may benefit from bisphosphonates or denosumab combined with locoregional treatments 3